Gossamer Bio (NASDAQ:GOSS) Trading 5.6% Higher
Shares of Gossamer Bio Inc (NASDAQ:GOSS) traded up 5.6% on Tuesday . The stock traded as high as $20.52 and last traded at $20.51, 253,960 shares changed hands during mid-day trading. An increase of 2% from the average session volume of 248,250 shares. The stock had previously closed at $19.43.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut Gossamer Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. ValuEngine raised Gossamer Bio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Gossamer Bio presently has an average rating of “Buy” and an average price target of $28.00.
The company has a market capitalization of $1.28 billion and a P/E ratio of -0.91. The company’s 50 day moving average price is $20.27. The company has a current ratio of 19.79, a quick ratio of 19.79 and a debt-to-equity ratio of 0.02.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. Bank of Montreal Can acquired a new stake in Gossamer Bio during the first quarter worth approximately $25,000. BNP Paribas Arbitrage SA acquired a new stake in Gossamer Bio during the second quarter worth approximately $42,000. JPMorgan Chase & Co. grew its stake in Gossamer Bio by 87.5% during the second quarter. JPMorgan Chase & Co. now owns 5,995 shares of the company’s stock worth $126,000 after purchasing an additional 2,798 shares during the period. Creative Planning acquired a new stake in Gossamer Bio during the first quarter worth approximately $260,000. Finally, Rhumbline Advisers acquired a new stake in Gossamer Bio during the first quarter worth approximately $271,000. 52.86% of the stock is owned by institutional investors and hedge funds.
Gossamer Bio Company Profile (NASDAQ:GOSS)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.